|
1
|
Quigley HA, Tielsch JM, Katz J and Sommer
A: Rate of progression in open-angle glaucoma estimated from
cross-sectional prevalence of visual field damage. Am J Ophthalmol.
122:355–363. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harper MM, Adamson L, Blits B, Bunge MB,
Grozdanic SD and Sakaguchi DS: Brain-derived neurotrophic factor
released from engineered mesenchymal stem cells attenuates
glutamate and hydrogen peroxide-mediated death of
staurosporine-differentiated RGC-5 cells. Exp Eye Res. 89:538–548.
2006. View Article : Google Scholar
|
|
3
|
Boland MV and Quigley HA: Risk factors and
open-angle glaucoma: Classification and application. J Glaucoma.
16:406–418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cruz-lñigo Y, Izquierdo NJ, García O and
Pérez R: Open-angle glaucoma in patients with diabetic retinopathy
at the Puerto Rico Medical Center. Bol Asoc Med P R. 104:10–13.
2012.
|
|
5
|
Chopra V, Varma R, Francis BA, Wu J,
Torres M and Azen SP: Los Angeles Latino Eye Study Group: Type 2
diabetes mellitus and the risk of open-angle glaucoma the Los
Angeles Latino Eye Study. Ophthalmology. 115:227–232.e1. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitchell P, Smith W, Chey T and Henley P:
Open-angle glaucoma and diabetes: The Blue Mountains Eye Study,
Australia. Ophthalmology. 104:712–718. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sato T and Roy S: Effect of high glucose
on fibronectin expression and cell proliferation in trabecular
meshwork cells. Invest Ophthalmol Vis Sci. 43:170–175.
2002.PubMed/NCBI
|
|
8
|
Nakamura M, Kanamori A and Negi A:
Diabetes mellitus as a risk factor for glaucomatous optic
neuropathy. Ophthalmologica. 219:1–10. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Q, Xu Y, Xie P, Cheng H, Song Q, Su
T, Yuan S and Liu Q: Retinal neurodegeneration in db/db mice at the
early period of diabetes. J Ophthalmol. 2015:7574122015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Y, Mao D, Chen X, Zhao L, Tian Q, Liu
C and Zhou BL: Decrease in retinal neuronal cells in
streptozotocin-induced diabetic mice. Mol Vis. 18:1411–1420.
2012.PubMed/NCBI
|
|
11
|
de Moraes G and Layton CJ: Therapeutic
targeting of diabetic retinal neuropathy as a strategy in
preventing diabetic retinopathy. Clin Exp Ophthalmol. 44:838–852.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Soto I, Howell GR, John CW, Kief JL, Libby
RT and John SW: DBA/2J mice are susceptible to diabetic nephropathy
and diabetic exacerbation of IOP elevation. PLoS One.
9:e1072912014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong VH, Bui BV and Vingrys AJ: Clinical
and experimental links between diabetes and glaucoma. Clin Exp
Optom. 94:4–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Faiq MA, Dada R, Saluja D and Dada T:
Glaucoma-diabetes of the brain: A radical hypothesis about its
nature and pathogenesis. Med Hypotheses. 82:535–546. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shen L, Walter S, Melles RB, Glymour MM
and Jorgenson E: Diabetes pathology and risk of primary open-angle
glaucoma: Evaluating causal mechanisms by using genetic
information. Am J Epidemiol. 183:147–155. 2016.PubMed/NCBI
|
|
16
|
Nakae J, Kido Y and Accili D: Distinct and
overlapping functions of insulin and IGF-I receptors. Endocr Rev.
22:818–835. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baumann CA and Saltiel AR: Spatial
compartmentalization of signal transduction in insulin action.
Bioessays. 23:215–222. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saltiel AR and Kahn CR: Insulin signalling
and the regulation of glucose and lipid metabolism. Nature.
414:799–806. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnston AM, Pirola L and Van Obberghen E:
Molecular mechanisms of insulin receptor substrate protein-mediated
modulation of insulin signalling. FEBS Lett. 546:32–36. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ola MS, Moore P, El-Sherbeny A, Roon P,
Agarwal N, Sarthy VP, Casellas P, Ganapathy V and Smith SB:
Expression pattern of sigma receptor 1 mRNA and protein in
mammalian retina. Brain Res Mol Brain Res. 95:86–95. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Campana G, Bucolo C, Murari G and
Spampinato S: Ocular hypotensive action of topical flunarizine in
the rabbit: Role of sigma 1 recognition sites. J Pharmacol Exp
Ther. 303:1086–1094. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bucolo C, Campana G, Di Toro R,
Cacciaguerra S and Spampinato S: Sigma1 recognition sites in rabbit
iris-ciliary body: Topical sigma1-site agonists lower intraocular
pressure. J Pharmacol Exp Ther. 289:1362–1369. 1999.PubMed/NCBI
|
|
23
|
Martin PM, Ola MS, Agarwal N, Ganapathy V
and Smith SB: The sigma receptor ligand (+)-pentazocine prevents
apoptotic retinal ganglion cell death induced in vitro by
homocysteine and glutamate. Brain Res Mol Brain Res. 123:66–75.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hayashi T and Su TP: Sigma-1 receptor
chaperones at the ER-mitochondrion interface regulate Ca(2+)
signaling and cell survival. Cell. 131:596–610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su TP and Hayashi T: Understanding the
molecular mechanism of sigma-1 receptors: Towards a hypothesis that
sigma-1 receptors are intracellular amplifiers for signal
transduction. Curr Med Chem. 10:2073–2080. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cobos EJ, Entrena JM, Nieto FR, Cendán CM
and Del Pozo E: Pharmacology and therapeutic potential of sigma(1)
receptor ligands. Curr Neuropharmacol. 6:344–366. 2009. View Article : Google Scholar
|
|
27
|
Sun X, Cheng F, Meng B, Yang B, Song W and
Yuan H: Pregnenolone sulfate decreases intraocular pressure and
changes expression of sigma receptor in a model of chronic ocular
hypertension. Mol Biol Rep. 39:6607–6614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta DeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao J, Mysona BA, Qureshi A, Kim L,
Fields T, Gonsalvez GB, Smith SB and Bollinger KE: (+)-Pentazocine
reduces NMDA-induced murine retinal ganglion cell death through a
σ1-dependent mechanism. Invest Ophthalmol Vis Sci. 57:453–461.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mueller BH II, Park Y, Ma HY, Dibas A,
Ellis DZ, Clark AF and Yorio T: Sigma-1 receptor stimulation
protects retinal ganglion cells from ischemia-like insult through
the activation of extracellular-signal-regulated kinases 1/2. Exp
Eye Res. 128:156–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mueller BH II, Park Y, Daudt DR III, Ma
HY, Akopova I, Stankowska DL, Clark AF and Yorio T: Sigma-1
receptor stimulation attenuates calcium influx through activated
L-type voltage gated calcium channels in purified retinal ganglion
cells. Exp Eye Res. 107:21–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kass MA, Heuer DK, Higginbotham EJ,
Johnson CA, Keltner JL, Miller JP, Parrish RK II, Wilson MR and
Gordon MO: The ocular hypertension treatment study: A randomized
trial determines that topical ocular hypotensive medication delays
or prevents the onset of primary open-angle glaucoma. Arch
Ophthalmol. 120:701–713, 829–830. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Heijl A, Leske MC, Bengtsson B, Hyman L
and Hussein M: Early Manifest Glaucoma Trial Group: Reduction of
intraocular pressure and glaucoma progression: Results from the
Early Manifest Glaucoma Trial. Arch Ophthalmol. 120:1268–1279.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alvarado J, Murphy C and Juster R:
Trabecular meshwork cellularity in primary open-angle glaucoma and
nonglaucomatous normals. Ophthalmology. 91:564–579. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rohen JW, Lütjen-Drecoll E, Flugel C,
Meyer M and Grierson I: Ultrastructure of the trabecular meshwork
in untreated cases of primary open-angle glaucoma (POAG). Exp Eye
Res. 56:683–692. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lutjen-Drecoll E, Rittig M, Rauterberg J,
Jander R and Mollenhauer J: Immunomicroscopical study of type VI
collagen in the trabecular meshwork of normal and glaucomatous
eyes. Exp Eye Res. 48:139–147. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tripathi RC: Pathologic anatomy of the
outflow pathway of aqueous humor in chronic simple glaucoma. Exp
Eye Res. 25:(Suppl). S403–S407. 1977. View Article : Google Scholar
|
|
38
|
Zhang X, Ognibene CM, Clark AF and Yorio
T: Dexamethasone inhibition of trabecular meshwork cell
phagocytosis and its modulation by glucocorticoid receptor beta.
Exp Eye Res. 84:275–284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cao Y, Wei H, Pfaffl M, Da B and Li Z:
Apoptosis of human trabecular meshwork cells induced by
transforming growth factor-beta2 in vitro. J Huazhong Univ Sci
Technolog Med Sci. 24:87–89, 94. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ziangirova GG and Antonova OV: Lipid
peroxidation in the pathogenesis of primary open-angle glaucoma.
Vestn Oftalmol. 119:54–55. 2003.(In Russian). PubMed/NCBI
|
|
41
|
Zhao D, Cho J, Kim MH, Friedman DS and
Guallar E: Diabetes, fasting glucose, and the risk of glaucoma: A
metaanalysis. Ophthalmology. 122:72–78. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ko F, Boland MV, Gupta P, Gadkaree SK,
Vitale S, Guallar E, Zhao D and Friedman DS: Diabetes, triglyceride
levels, and other risk factors for glaucoma in the National Health
and Nutrition Examination Survey 2005–2008. Invest Ophthalmol Vis
Sci. 57:2152–2157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mitchell P, Smith W, Chey T and Healey PR:
Open-angle glaucoma and diabetes: The Blue Mountains eye study,
Australia. Ophthalmology. 104:712–718. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Klein BE, Klein R and Jensen SC:
Open-angle glaucoma and older-onset diabetes. The Beaver Dam Eye
Study. Ophthalmology. 101:1173–1177. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xie L, Chen H, Overbeek PA and Reneker LW:
Elevated insulin signaling disrupts the growth and differentiation
pattern of the mouse lens. Mol Vis. 13:397–407. 2007.PubMed/NCBI
|
|
46
|
Zamanillo D, Romero L, Merlos M and Vela
JM: Sigma 1 receptor: A new therapeutic target for pain. Eur J
Pharmacol. 716:78–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mori T, Hayashi T, Hayashi E and Su TP:
Sigma-1 receptor chaperone at the ER-mitochondrion interface
mediates the mitochondrion-ER-nucleus signaling for cellular
survival. PLoS One. 8:e769412013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Su TP, Hayashi T, Maurice T, Buch S and
Ruoho AE: The sigma-1 receptor chaperone as an inter-organelle
signaling modulator. Trends Pharmacol Sci. 31:557–566. 2010.
View Article : Google Scholar : PubMed/NCBI
|
